What are the considerations for topical therapies to treat mycosis fungoides/Sezary syndrome (MF/SS) in cutaneous T-cell lymphoma (CTCL) non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


In general, topical therapies are recommended for localized disease (stages IA, IB and IIA), with systemic or combination systemic and topical therapies beginning with stage IIB. Systemic therapies may also be considered in patients with early-stage disease that does not respond to topical treatments. [26, 27, 2]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!